CA2535506A1 - Pharmaceutical compositions for preventing breast and ovarian cancer - Google Patents
Pharmaceutical compositions for preventing breast and ovarian cancer Download PDFInfo
- Publication number
- CA2535506A1 CA2535506A1 CA002535506A CA2535506A CA2535506A1 CA 2535506 A1 CA2535506 A1 CA 2535506A1 CA 002535506 A CA002535506 A CA 002535506A CA 2535506 A CA2535506 A CA 2535506A CA 2535506 A1 CA2535506 A1 CA 2535506A1
- Authority
- CA
- Canada
- Prior art keywords
- selenium
- composition
- breast
- brca1
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 38
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 37
- 210000000481 breast Anatomy 0.000 title claims abstract description 33
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 206010033128 Ovarian cancer Diseases 0.000 title claims description 16
- 239000011669 selenium Substances 0.000 claims abstract description 86
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 84
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 81
- 101150072950 BRCA1 gene Proteins 0.000 claims abstract description 34
- 230000035772 mutation Effects 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000000969 carrier Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 8
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims abstract description 5
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims abstract description 5
- QYHFIVBSNOWOCQ-UHFFFAOYSA-N selenic acid Chemical compound O[Se](O)(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000016491 selenocysteine Nutrition 0.000 claims abstract description 5
- 229940055619 selenocysteine Drugs 0.000 claims abstract description 5
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims abstract description 4
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002718 selenomethionine Drugs 0.000 claims abstract description 4
- UEQANLFPOFICBH-UHFFFAOYSA-N methylseleninic acid Chemical compound C[Se](O)=O UEQANLFPOFICBH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940091258 selenium supplement Drugs 0.000 claims description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 16
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical group [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 13
- 229960001471 sodium selenite Drugs 0.000 claims description 13
- 235000015921 sodium selenite Nutrition 0.000 claims description 13
- 239000011781 sodium selenite Substances 0.000 claims description 13
- 206010071980 BRCA1 gene mutation Diseases 0.000 claims description 9
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 229940065287 selenium compound Drugs 0.000 claims description 6
- 150000003343 selenium compounds Chemical class 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 229930014626 natural product Natural products 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 4
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000644 isotonic solution Substances 0.000 claims description 3
- SPVXKVOXSXTJOY-UHFFFAOYSA-N selane Chemical class [SeH2] SPVXKVOXSXTJOY-UHFFFAOYSA-N 0.000 claims description 2
- 150000003342 selenium Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 229910018143 SeO3 Inorganic materials 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 229940082569 selenite Drugs 0.000 claims 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 abstract description 30
- 108700020463 BRCA1 Proteins 0.000 abstract description 28
- -1 selenomethylcysteine Chemical compound 0.000 abstract description 3
- 125000003748 selenium group Chemical group *[Se]* 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 17
- 230000009469 supplementation Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 208000037088 Chromosome Breakage Diseases 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- RVIXKDRPFPUUOO-UHFFFAOYSA-N dimethylselenide Chemical compound C[Se]C RVIXKDRPFPUUOO-UHFFFAOYSA-N 0.000 description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- 230000002113 chemopreventative effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108700010154 BRCA2 Genes Proteins 0.000 description 4
- 101150008921 Brca2 gene Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003346 selenoethers Chemical class 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- JMQMNWIBUCGUDO-UHFFFAOYSA-N L-Djenkolic acid Natural products OC(=O)C(N)CSCSCC(N)C(O)=O JMQMNWIBUCGUDO-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- JMQMNWIBUCGUDO-WHFBIAKZSA-N L-djenkolic acid Chemical compound OC(=O)[C@@H](N)CSCSC[C@H](N)C(O)=O JMQMNWIBUCGUDO-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 2
- UWZXJRBXKTZILP-UHFFFAOYSA-L calcium;selenite Chemical compound [Ca+2].[O-][Se]([O-])=O UWZXJRBXKTZILP-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- SMVMOIXTOKYXAN-UHFFFAOYSA-L dilithium;selenite Chemical compound [Li+].[Li+].[O-][Se]([O-])=O SMVMOIXTOKYXAN-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- WBRSXICUEVGXAB-UHFFFAOYSA-N selenonic acid Chemical compound O[SeH](=O)=O WBRSXICUEVGXAB-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VKUCHMVHDHABFA-UHFFFAOYSA-N 2-amino-2-(sulfanylmethyl)butanoic acid Chemical compound CCC(N)(CS)C(O)=O VKUCHMVHDHABFA-UHFFFAOYSA-N 0.000 description 1
- YVYYJWYPTKQLNY-UHFFFAOYSA-N 2-amino-2-sulfanyloctanoic acid Chemical compound CCCCCCC(N)(S)C(O)=O YVYYJWYPTKQLNY-UHFFFAOYSA-N 0.000 description 1
- FVNKWWBXNSNIAR-UHFFFAOYSA-N 2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CNC(S)=N1 FVNKWWBXNSNIAR-UHFFFAOYSA-N 0.000 description 1
- ROYIRMLRQNTCAO-UHFFFAOYSA-N 2-amino-4-ethyl-2-sulfanylhexanoic acid Chemical compound CCC(CC)CC(N)(S)C(O)=O ROYIRMLRQNTCAO-UHFFFAOYSA-N 0.000 description 1
- ZJFISDZECFYPMA-UHFFFAOYSA-N 2-amino-4-methyl-2-sulfanylpentanoic acid Chemical compound CC(C)CC(N)(S)C(O)=O ZJFISDZECFYPMA-UHFFFAOYSA-N 0.000 description 1
- BZMBZISTEDVTDS-UHFFFAOYSA-N 2-amino-5-methyl-2-sulfanylhexanoic acid Chemical compound CC(C)CCC(N)(S)C(O)=O BZMBZISTEDVTDS-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010071981 BRCA2 gene mutation Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000005886 chromosome breakage Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VZZSRKCQPCSMRS-UHFFFAOYSA-N dipotassium;selenium(2-) Chemical compound [K+].[K+].[Se-2] VZZSRKCQPCSMRS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000004731 environmental carcinogenesis Effects 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102200067153 rs28897672 Human genes 0.000 description 1
- 238000001629 sign test Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- VPQBLCVGUWPDHV-UHFFFAOYSA-N sodium selenide Chemical compound [Na+].[Na+].[Se-2] VPQBLCVGUWPDHV-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.361597 | 2003-08-11 | ||
| PL361597A PL214402B1 (pl) | 2003-08-11 | 2003-08-11 | Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika |
| PCT/PL2004/000063 WO2005013951A2 (en) | 2003-08-11 | 2004-08-10 | Pharmaceutical compositions for preventing breast and ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2535506A1 true CA2535506A1 (en) | 2005-02-17 |
Family
ID=34132453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002535506A Abandoned CA2535506A1 (en) | 2003-08-11 | 2004-08-10 | Pharmaceutical compositions for preventing breast and ovarian cancer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1660060A2 (ja) |
| JP (1) | JP2007502270A (ja) |
| KR (1) | KR20060066719A (ja) |
| CN (1) | CN1835740A (ja) |
| AU (1) | AU2004263070A1 (ja) |
| CA (1) | CA2535506A1 (ja) |
| EA (1) | EA200600386A1 (ja) |
| PL (1) | PL214402B1 (ja) |
| WO (1) | WO2005013951A2 (ja) |
| ZA (1) | ZA200602081B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2581101A1 (en) * | 2004-09-21 | 2006-03-30 | Velacor Therapeutics Pty Ltd | Inorganic selenium for treatment of cancer |
| KR20090127939A (ko) * | 2007-03-26 | 2009-12-14 | 디코드 제네틱스 이에이치에프 | 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 ２ 및 염색체 １６ 상의 유전적 변이 |
| CN100548311C (zh) | 2007-06-13 | 2009-10-14 | 中国科学技术大学 | 硒代硫酸钠在制备临床补硒和治疗癌症药物中的应用及快速制备方法 |
| WO2009043106A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Inorganic selenium and angiogenesis |
| US20110105342A1 (en) * | 2008-03-13 | 2011-05-05 | Jan Lubinski | Method for determining reduced predisposition to cancer based on genetic profile |
| KR101026291B1 (ko) * | 2008-06-30 | 2011-03-31 | 주식회사 태강 | SeO2 doped W-Mo-Li 화합물을 함유한 항암제 조성물 |
| GB0916010D0 (en) * | 2009-09-11 | 2009-10-28 | Isis Innovation | JMJD2 demethylase inhibitors |
| WO2012067525A1 (en) | 2010-11-18 | 2012-05-24 | Pomorski Uniwersytet Medyczny | Genotypes and selenium level as a markers of breast/ovarian cancer risk in brca1 mutation carriers |
| WO2012130609A1 (en) | 2011-04-01 | 2012-10-04 | Iasomai Ab | New combination comprising n-acetyl-l-cysteine and its use |
| CN114533753A (zh) * | 2013-03-15 | 2022-05-27 | 全技术公司 | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 |
| JP6313479B2 (ja) * | 2014-03-14 | 2018-04-18 | オールテック，インク． | 有機セレン化合物の組成物およびその使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19825746A1 (de) * | 1998-06-09 | 1999-12-16 | Biosyn Arzneimittel Gmbh | Kombination von Selen-haltigen Verbindungen mit Zytostatika |
-
2003
- 2003-08-11 PL PL361597A patent/PL214402B1/pl unknown
-
2004
- 2004-08-10 CN CNA2004800231246A patent/CN1835740A/zh active Pending
- 2004-08-10 WO PCT/PL2004/000063 patent/WO2005013951A2/en active Application Filing
- 2004-08-10 EA EA200600386A patent/EA200600386A1/ru unknown
- 2004-08-10 JP JP2006523155A patent/JP2007502270A/ja not_active Withdrawn
- 2004-08-10 CA CA002535506A patent/CA2535506A1/en not_active Abandoned
- 2004-08-10 AU AU2004263070A patent/AU2004263070A1/en not_active Abandoned
- 2004-08-10 EP EP04775169A patent/EP1660060A2/en not_active Withdrawn
- 2004-08-10 KR KR1020067002810A patent/KR20060066719A/ko not_active Application Discontinuation
-
2006
- 2006-03-10 ZA ZA200602081A patent/ZA200602081B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060066719A (ko) | 2006-06-16 |
| WO2005013951A3 (en) | 2005-09-15 |
| WO2005013951A2 (en) | 2005-02-17 |
| PL214402B1 (pl) | 2013-07-31 |
| ZA200602081B (en) | 2007-05-30 |
| JP2007502270A (ja) | 2007-02-08 |
| EP1660060A2 (en) | 2006-05-31 |
| CN1835740A (zh) | 2006-09-20 |
| EA200600386A1 (ru) | 2006-12-29 |
| AU2004263070A1 (en) | 2005-02-17 |
| PL361597A1 (en) | 2005-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200602081B (en) | Pharmaceutical compositions for preventing breast and ovarian cancer | |
| Prasad | Zinc: an antioxidant and anti-inflammatory agent: role of zinc in degenerative disorders of aging | |
| Prasad et al. | Zinc in cancer prevention | |
| Mariani et al. | Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects | |
| Ou et al. | Role and mechanism of ferroptosis in neurological diseases | |
| KR102090836B1 (ko) | 세포 정제를 촉진하기 위한 경구 제제 | |
| Killilea et al. | Mineral requirements for mitochondrial function: A connection to redox balance and cellular differentiation | |
| Dröge | The plasma redox state and ageing | |
| US20050069594A1 (en) | Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer | |
| Dresen et al. | Overview of oxidative stress and the role of micronutrients in critical illness | |
| Feng et al. | Radioprotective effect of lactoferrin in mice exposed to sublethal X‑ray irradiation | |
| WO2015004266A1 (en) | Personalized nutrient compositions and methods for producing these | |
| Tiwari et al. | Effect of iron and folate supplementation on Pb levels in pregnant anemic women: a prospective study | |
| Kumar et al. | Zinc deficiency and its effect on the brain: an update | |
| Galchenko et al. | Association of microelementos with the risk of hypochromic anemia in vegetarians and vegans | |
| El-Bassyouni et al. | Oxidative stress-a phenotypic hallmark of Fanconi anemia and Down syndrome: The effect of antioxidants | |
| Baumgartner et al. | Antioxidant effects in the development of Ehrlich ascites carcinoma | |
| MXPA06001632A (en) | Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer | |
| Chaitanya et al. | Mineral Deficiencies: a root cause for reduced longevity in mammals | |
| Hurley et al. | Trace elements in man and animals 6 | |
| Moesgaard et al. | The need for speciation to realise the potential of selenium in disease prevention | |
| US20100291235A1 (en) | Composition for treating sterile inflammation | |
| Kumar | Copper deficiency myeloneuropathy | |
| Al-Basrawi et al. | Antioxidant Effect of Folic Acid and its Relation to Salivary Proteins and Oral Health | |
| Guarnieri et al. | Muscle cathepsin D activity, and RNA, DNA and protein content in maintenance hemodialysis patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |